CancerDrs

Colorectal Cancer clinical trials in Massachusetts

56 actively recruiting colorectal cancer trials at 18 sites across Massachusetts.

Data from ClinicalTrials.gov · last refreshed

Phase 2, Phase 3 Recruiting Academic/Other

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Massachusetts:
  • Beverly Hospital — Beverly, Massachusetts
  • Tufts Medical Center — Boston, Massachusetts
  • Boston Medical Center — Boston, Massachusetts
  • Dana-Farber Cancer Institute at Boston Medical Center - Brighton — Brighton, Massachusetts
  • Lahey Hospital and Medical Center — Burlington, Massachusetts
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limit…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06205485
Sites in Massachusetts:
  • Beverly Hospital — Beverly, Massachusetts
  • Lahey Hospital and Medical Center — Burlington, Massachusetts
  • Addison Gilbert Hospital — Gloucester, Massachusetts
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to b…

Sponsor: Rapamycin Holdings Inc.
NCT ID: NCT06950385
Sites in Massachusetts:
  • Dana Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

The Cancer of the Pancreas Screening-5 CAPS5)Study

Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.

Sponsor: Johns Hopkins University
NCT ID: NCT02000089
Sites in Massachusetts:
  • Dana Farber Cancer Center, Harvard University — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.

Sponsor: Surgimab
NCT ID: NCT03659448
Sites in Massachusetts:
  • Massachusetts General Hospital — Boston, Massachusetts
  • University of Massachusetts — Worcester, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in Massachusetts:
  • Massachusetts General Hospital — Boston, Massachusetts
  • Dana Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Massachusetts:
  • Massachusetts General Hospital — Boston, Massachusetts
  • Dana Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types ar…

Sponsor: Vyriad, Inc.
NCT ID: NCT04291105
Sites in Massachusetts:
  • Massachusetts General Hospital Cancer Center — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given al…

Sponsor: AbbVie
NCT ID: NCT07023289
Sites in Massachusetts:
  • Massachusetts General Hospital /ID# 273608 — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Massachusetts:
  • Dana Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…

Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Massachusetts:
  • Massachusetts General Hospital — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it…

Sponsor: Bayer
NCT ID: NCT06760819
Sites in Massachusetts:
  • Dana-Farber Cancer Institute - Oncology Department — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …

Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Massachusetts:
  • Dana-Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population i…

Sponsor: LigaChem Biosciences, Inc.
NCT ID: NCT05941507
Sites in Massachusetts:
  • Dana Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…

Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in Massachusetts:
  • Dana Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

The goal of this clinical study is to learn more about the study drug, Denikitug (DEN, GS-1811), to evaluate the efficacy and safety of Denikitug Monotherapy and Denikitug-based Combinations in participants with advanced microsatellite sta…

Sponsor: Gilead Sciences
NCT ID: NCT07527858
Sites in Massachusetts:
  • Beth Israel Deaconess Medical Center — Boston, Massachusetts
  • Dana-Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER

This is research study is assessing the effects of 6-g daily use of freeze-dried instant coffee on liver fat and fibrosis and the gut microbiome and metabolome in patients who have completed routine treatment (including surgery, chemothera…

Sponsor: Massachusetts General Hospital
NCT ID: NCT05692024
Sites in Massachusetts:
  • Massachusetts General Hospital — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Massachusetts:
  • Exelixis Clinical Site #7 — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is …

Sponsor: Pfizer
NCT ID: NCT05355701
Sites in Massachusetts:
  • Brigham and Women's Hospital — Boston, Massachusetts
  • Dana-Farber Cancer Institute — Boston, Massachusetts
  • DFCI Chestnut Hill — Newton, Massachusetts
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Phase 1/1b Study of IAM1363 in HER2 Cancers

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Massachusetts:
  • Massachusetts General Hospital — Boston, Massachusetts
  • Dana Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT06131840
Sites in Massachusetts:
  • Beth Israel Deaconess Medical Center — Boston, Massachusetts
  • Beth Israel Deaconess Medical Center — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is …

Sponsor: Eli Lilly and Company
NCT ID: NCT07213791
Sites in Massachusetts:
  • Massachusetts General Hospital — Boston, Massachusetts
  • Beth Israel Deaconess Medical Center — Boston, Massachusetts
View on ClinicalTrials.gov →

Showing 25 of 56 trials with sites in Massachusetts. See all colorectal cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15